Spots Global Cancer Trial Database for Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
Official Title: Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+)
Study ID: NCT02151149
Study Description
Brief Summary: Study comparing two regimens of nab-paclitaxel and carboplatin combination in elderly subjects (≥ 70 years old) with advanced NSCLC
Detailed Description: This is a Phase IV, randomized, open-label, multicenter study of continuous weekly versus weekly times three with one-week break nab-paclitaxel in combination with carboplatin as first-line treatment in elderly subjects (≥ 70 years old) with advanced non small cell lung cancer who have not received prior chemotherapy for their advanced disease and are not candidates for curative surgery or radiation therapy. The primary study endpoint is the percentage of subjects with either peripheral neuropathy or myelosuppression adverse events. Patients will continue treatment until they develop progressive disease, unacceptable side-effects or wish to withdraw from the study, according to local standard of care. Patients will have radiographic evaluations every 6 weeks while on treatment.
Eligibility
Minimum Age: 70 Years
Eligible Ages: OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Arizona Clinical Research Center, Tucson, Arizona, United States
Genesis Cancer Center, Hot Springs, Arkansas, United States
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
Saint Jude Heritage Medical Center, Fullerton, California, United States
Global Cancer Research Institute (GCRI), Inc., Gilroy, California, United States
Ventura County Hematology-Oncology Specialists, Oxnard, California, United States
Central Coast Medical Oncology Corporation, Santa Maria, California, United States
University of California Los Angeles, Santa Monica, California, United States
Rocky Mountain Cancer Centers, LLP, Denver, Colorado, United States
St Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States
Lynn Cancer Institute, Boca Raton, Florida, United States
Baptist Cancer Inst, Jacksonville, Florida, United States
Ocala Oncology Center, Ocala, Florida, United States
Florida Hospital Cancer Institute, Orlando, Florida, United States
Northshore University Healthsystem Research Institute, Evanston, Illinois, United States
Oncology Specialists, S.C., Niles, Illinois, United States
Franciscan St. Francis Health, Indianapolis, Indiana, United States
Cancer Center of Kansas, Wichita, Kansas, United States
Western Kentucky Hematology and Oncology Group, Paducah, Kentucky, United States
West Jeffersion Medical Center, Marrero, Louisiana, United States
Ochsner Medical Institutions, New Orleans, Louisiana, United States
Medstar Health Research Institute, Baltimore, Maryland, United States
Reliant Medical Group, Worcester, Massachusetts, United States
Henry Ford Health System, Detroit, Michigan, United States
Nebraska Methodist Hospital, Omaha, Nebraska, United States
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
Center for Cancer and Hematologic Disease, Cherry Hill, New Jersey, United States
Regional Cancer Care Associates LLC, East Brunswick, New Jersey, United States
Saint Barnabas Medical Center, Livingston, New Jersey, United States
Carol G Simon Cancer Center, Morristown, New Jersey, United States
Somerset Hematology-Oncology Associates, Somerville, New Jersey, United States
Regional Cancer Care Associates LLC- Sparta division, Sparta, New Jersey, United States
Montefiore Medical Center, Bronx, New York, United States
Brookdale University Hospital and Medical Center, Brooklyn, New York, United States
Broome Oncology, LLC, Johnson City, New York, United States
Clinical Research Alliance, Lake Success, New York, United States
SUNY Upstate Medical University Medicine Oncology, Syracuse, New York, United States
Lineberger Cancer Center, Chapel Hill, North Carolina, United States
Levine Cancer Institute, Charlotte, North Carolina, United States
Forsyth Memorial Hospital, Inc., Winston-Salem, North Carolina, United States
St Elizabeth Hospital, Youngstown, Ohio, United States
Cancer Centres of Southwest Okahoma Research, Lawton, Oklahoma, United States
Good Samaritan Hospital Corvalis, Corvallis, Oregon, United States
Oregon Health and Science University, Portland, Oregon, United States
Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States
Thomas Jefferson University Medical College, Philadelphia, Pennsylvania, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
Texas Oncology, P.A.-Amarillo, Amarillo, Texas, United States
Baylor University Medical Center at Dallas, Dallas, Texas, United States
UTMB Galveston, Galveston, Texas, United States
Texas Oncology, PA - Longview, Longview, Texas, United States
Virginia Mason Cancer Center, Seattle, Washington, United States
Northwest Cancer Specialists, P.C., Vancouver, Washington, United States
Contact Details
Name: Teng Jin Ong
Affiliation: Celgene
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
